Hong Kong Stock Exchange · Healthcare
Invest in GenFleet Therapeutics (Shanghai) stock from India
Indian and foreign residents can buy GenFleet Therapeutics (Shanghai) (2595) shares directly through Paasa.
By Paasa · Updated
GenFleet Therapeutics (Shanghai) at a glance
- Price
- HK$32.10+HK$2.52 (8.52%)
- Market cap
- HK$11.29B
- Day range
- HK$29.56 – HK$32.90
- P/E
- —
- Dividend yield
- None
- Volume
- 3.81M
- 1 month
- +1.97%
- 6 months
- -1.59%
- YTD
- +34.76%
- 1 year
- -21.36%
- 5 years
- —
How to invest in GenFleet Therapeutics (Shanghai) from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to HKD when you buy.
Step 3
Search 2595 and buy
Find GenFleet Therapeutics (Shanghai) by name or by its ticker, 2595, and place your order. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
Why invest in GenFleet Therapeutics (Shanghai) from India
What GenFleet Therapeutics (Shanghai) does
GenFleet Therapeutics (Shanghai) Inc., a biopharmaceutical company, develops treatment options in the fields of oncology, autoimmune, and inflammatory diseases in the United States. The company develops GFH375, an orally bioavailable small molecule inhibitor of Kirsten rat sarcoma (KRAS) G12C in a Phase III trial for the treatment of pancreatic cancer, as well as in Phase II trials for the treatment of non-small cell lung cancer (NSCLC) and BTC, and in a Phase I trial for the treatment of solid tumors; GFH925, a small molecule selective inhibitor of KRAS G12C in a Phase II trial for the tre… GenFleet Therapeutics (Shanghai) operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy GenFleet Therapeutics (Shanghai) stock from India?
Yes. Indian residents and NRIs can buy GenFleet Therapeutics (Shanghai) (2595) shares directly through Paasa. GenFleet Therapeutics (Shanghai) is listed on the Hong Kong Stock Exchange, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full GenFleet Therapeutics (Shanghai) share?
Usually more than one, and not a fraction: many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. At HK$32.10 a share, size the order by the lot, not by the share.
How are GenFleet Therapeutics (Shanghai) dividends taxed for Indian investors?
GenFleet Therapeutics (Shanghai) trades on the Hong Kong Stock Exchange but is domiciled in China, so any withholding on its dividends follows that country's rules rather than those of Hong Kong. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell GenFleet Therapeutics (Shanghai) shares?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the HKD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.